

PMBI / S-Network Medical Breakthroughs Index

Index fact sheet as of January 31, 2024

PMBI Facts

Ticker
Price Return: PMBI
Total Return: PMBITR
Net Total Return: PMBINT

Index Launch
January 31, 2014

Base Value
4,473.04 on August 27, 2014

Index Calculation
Every fifteen (15) seconds

Reconstitution Dates
Every 3rd Friday of March and
September

Rebalancing Dates
Every 3rd Friday of March, June,
September and December

Index Rules
Available at vettafi.com

Portfolio Characteristics

Number of Companies: 93

Company Size by Market
Capitalization (millions):

Average: \$1,617
Median: \$1,204
Largest: \$7,554
Smallest: \$55

Performance Data

3 Month: 35.6%
6 Month: 3.7%
YTD: 0.7%
1 Year: 2.3%
Annualized 3 Year: -15.6%
Annualized 5 Year: 1.1%
Annualized 8 Year: 5.8%
Standard Deviation: 28.7%
Sharpe Ratio: 0.32

An index of small and mid-cap biotechnology stocks listed on US stock exchanges that have one or more drugs in either Phase II or Phase III US FDA clinical trials.

Performance of \$1,000 invested



Top 10 Constituents

Company Name	Sector	Ticker	Index Weight
Vaxcyte Inc		PCVX	4.6%
Cerevel Therapeutics Holdings Inc		CERE	4.0%
Alkermes PLC		ALKS	3.1%
Revolution Medicines Inc		RVMD	3.0%
Axsome Therapeutics Inc.		AXSM	2.9%
Acadia Pharmaceuticals Inc		ACAD	2.8%
RayzeBio Inc		RYZB	2.5%
Immunocore Holdings plc		IMCR	2.4%
Xenon Pharmaceuticals Inc		XENE	2.3%
MoonLake Immunotherapeutics		MLTX	2.1%
Total:			29.7%

Country Weightings



VettaFi, a data, analytics, and thought leadership company, is transforming financial services from an industry to a community — one relationship at a time. In addition to providing interactive online tools and research, VettaFi offers asset managers an array of indexing and digital distribution solutions to innovate and scale their businesses. With billions in assets benchmarked to its indices — and more than 200 customers globally — asset managers look to VettaFi for benchmarks and best-in-class index solutions. VettaFi owns and administers S-Network Global indexes.

It is not possible to invest directly in an index. Index performance does not reflect the deduction of any fees or expenses. VettaFi does not sponsor, endorse, sell, or promote any investment product linked to or based on the S-Network Medical Breakthroughs Index. Performance is provided on a total-return basis. Correlation is based on monthly data over the trailing 96 month period. Percentage of positive months, standard deviation, value of \$1,000, and Sharpe ratio comparisons are based on monthly data over the trailing 96 month period. The S-Network Medical Breakthroughs Index is the exclusive property of VettaFi, which shall have no liability for any errors or omissions in calculating the Index.